Helicos Reports Growing Net Loss in Q2 in Preparation for Product Launch
 
Helicos BioSciences, preparing the launch of its HeliScope next-generation sequencer later this year, reported growing losses and increasing R&D expenses for the second quarter this week.
 
For the quarter ended June 30, the company had $143,000 in grant revenue from the National Institutes of Health, compared to no revenues during last year’s quarter.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.